Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer.
about
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma ModelBig opportunities for small molecules in immuno-oncology.Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice.Mutation in the Drosophila melanogaster adenosine receptor gene selectively decreases the mosaic hyperplastic epithelial outgrowth rates in wts or dco heterozygous flies.Hypoxia-Inducible Factor-2α Limits Natural Killer T Cell Cytotoxicity in Renal Ischemia/Reperfusion Injury.Extracellular adenosine signaling in molecular medicineThe critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging.Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities.Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1.Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies.Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.Adenosine metabolism, immunity and joint health.Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
P2860
Q26782214-75D085FC-1434-4091-B92D-907174E93904Q34487689-084E2B42-CD73-423E-B9B6-09E87E540F07Q34695338-356012C9-6F7A-4618-991E-6E15EEDE70F3Q35107197-0EB676C2-A061-4875-910D-B40766B7F8BFQ36417929-749EA424-1095-41A6-B86F-8FFF596F2C4FQ36585539-ED079808-E837-450B-84AF-5A6C47E4AD5FQ37413162-5D5B0478-B1F7-409F-ABCA-6FFF44BBA2A7Q37468697-3E375589-2E9B-4597-BCDF-238A74204DC1Q38209586-68682D94-3417-43DB-ACD2-7571EFB366CDQ38765118-DB692DC9-9EDE-4E33-A4E2-2C8C9A6112FEQ38767892-3B8602EB-A29D-4873-AF95-511C6D14D539Q39721664-5258A406-6895-45C4-825A-A50AEFDDBFE3Q41830617-AC008D03-3AB4-4D30-BE9A-3DEBB3A608EFQ42094877-1E6BCD49-5CF4-4C3A-B514-279D2D576B89Q47131425-CB1CB3C5-F038-458F-BC71-CC0C0B23614FQ50086989-B18FE719-4964-4855-B2AB-22A4C7BC59BFQ52323624-AEE7E46F-702C-469F-A1DF-1FF96D31BC72Q55386131-7BBCCE2B-724F-4FFB-B846-296BB2FF6EE8
P2860
Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Targeting the hypoxia-adenosin ...... ptive immunotherapy of cancer.
@ast
Targeting the hypoxia-adenosin ...... ptive immunotherapy of cancer.
@en
type
label
Targeting the hypoxia-adenosin ...... ptive immunotherapy of cancer.
@ast
Targeting the hypoxia-adenosin ...... ptive immunotherapy of cancer.
@en
prefLabel
Targeting the hypoxia-adenosin ...... ptive immunotherapy of cancer.
@ast
Targeting the hypoxia-adenosin ...... ptive immunotherapy of cancer.
@en
P2860
P1476
Targeting the hypoxia-adenosin ...... ptive immunotherapy of cancer.
@en
P2093
Michail Sitkovsky
P2860
P2888
P304
P356
10.1007/S00109-013-1001-9
P577
2013-01-20T00:00:00Z